JPWO2021186056A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021186056A5 JPWO2021186056A5 JP2022555951A JP2022555951A JPWO2021186056A5 JP WO2021186056 A5 JPWO2021186056 A5 JP WO2021186056A5 JP 2022555951 A JP2022555951 A JP 2022555951A JP 2022555951 A JP2022555951 A JP 2022555951A JP WO2021186056 A5 JPWO2021186056 A5 JP WO2021186056A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence seq
- seq
- sequence
- lcvr
- hcvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 210000003289 regulatory T cell Anatomy 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305298.0 | 2020-03-20 | ||
| EP20305298 | 2020-03-20 | ||
| PCT/EP2021/057132 WO2021186056A1 (fr) | 2020-03-20 | 2021-03-19 | Récepteur antigénique chimérique spécifique de cd45rc humain et ses utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518538A JP2023518538A (ja) | 2023-05-02 |
| JPWO2021186056A5 true JPWO2021186056A5 (fr) | 2024-03-27 |
Family
ID=71465223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555951A Pending JP2023518538A (ja) | 2020-03-20 | 2021-03-19 | ヒトｃｄ４５ｒｃに特異的なキメラ抗原受容体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230147657A1 (fr) |
| EP (1) | EP4121457A1 (fr) |
| JP (1) | JP2023518538A (fr) |
| KR (1) | KR20230004510A (fr) |
| CN (1) | CN115916823A (fr) |
| AU (1) | AU2021237790A1 (fr) |
| BR (1) | BR112022018795A2 (fr) |
| CA (1) | CA3172120A1 (fr) |
| IL (1) | IL296546A (fr) |
| MX (1) | MX2022011683A (fr) |
| WO (1) | WO2021186056A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230032871A1 (en) * | 2021-07-14 | 2023-02-02 | Innovative Cellular Therapeutics Holdings, Ltd. | Recombinant Viral Particle for Gene and/or Cellular Therapy |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| WO1998056915A2 (fr) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Polypeptides d'anticorps artificiels |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU2001243288B2 (en) | 2000-02-24 | 2005-11-24 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2004094642A2 (fr) | 2003-04-24 | 2004-11-04 | Fondazione Centro San Raffaele Del Monte Tabor | Vecteurs lentiviraux portant des promoteurs bidirectionnels de synthese, et leurs utilisations |
| EP3363907A1 (fr) | 2004-05-27 | 2018-08-22 | The Trustees of the University of Pennsylvania | Nouvel antigène artificiel présentant des cellules et utilisations associées |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP1929073A4 (fr) | 2005-09-27 | 2010-03-10 | Amunix Inc | Produits pharmaceutiques proteiques et utilisations de ceux-ci |
| GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2596011B1 (fr) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Méthodes et compositions pour modifier un locus hla |
| CA2832540C (fr) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recepteurs d'antigene chimerique de variant iii du recepteur du facteur de croissance anti-epidermique et leur utilisation pour le traitement du cancer |
| DK3401400T3 (da) | 2012-05-25 | 2019-06-03 | Univ California | Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering |
| WO2014093595A1 (fr) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Systèmes de composants de crispr-cas, procédés et compositions pour la manipulation de séquences |
| KR20150105634A (ko) | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 개선된 시스템, 방법 및 효소 조성물의 유전자 조작 및 최적화 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| JP6692343B2 (ja) | 2014-08-01 | 2020-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 薬物としての使用のための抗ｃｄ４５ｒｃ抗体 |
| JP2019513347A (ja) * | 2016-03-04 | 2019-05-30 | ノバルティス アーゲー | 複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用 |
| EP3652306A1 (fr) * | 2017-07-13 | 2020-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour augmenter la capacité immunosuppressive et d'expansion d'une population de cd8 + cd45rclow/-tregs |
| EP3498293A1 (fr) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Traitement de maladies monogéniques avec un anticorps anti-cd45rc |
| EP3626265A1 (fr) * | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-cd45rc anti-humains et leurs utilisations |
-
2021
- 2021-03-19 AU AU2021237790A patent/AU2021237790A1/en active Pending
- 2021-03-19 US US17/912,726 patent/US20230147657A1/en active Pending
- 2021-03-19 JP JP2022555951A patent/JP2023518538A/ja active Pending
- 2021-03-19 MX MX2022011683A patent/MX2022011683A/es unknown
- 2021-03-19 IL IL296546A patent/IL296546A/en unknown
- 2021-03-19 KR KR1020227036234A patent/KR20230004510A/ko active Search and Examination
- 2021-03-19 CN CN202180036571.9A patent/CN115916823A/zh active Pending
- 2021-03-19 BR BR112022018795A patent/BR112022018795A2/pt unknown
- 2021-03-19 CA CA3172120A patent/CA3172120A1/fr active Pending
- 2021-03-19 WO PCT/EP2021/057132 patent/WO2021186056A1/fr active Application Filing
- 2021-03-19 EP EP21712190.4A patent/EP4121457A1/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210009688A1 (en) | Anti-pd-1 antibody and use thereof | |
| AU2009224690B2 (en) | Agent for treating disease | |
| US9334325B2 (en) | Method for treating psoriasis | |
| US7524498B2 (en) | Human immunomodulatory monoclonal antibodies for the treatment of cancer | |
| US7829086B2 (en) | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| US8664363B2 (en) | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| CA2819520C (fr) | Anticorps anti cd4 servant a prevenir en particulier le rejet de greffon contre hote | |
| JP2020528768A5 (fr) | ||
| AU2016359683A1 (en) | Heterodimeric antibodies that bind CD3 and CD38 | |
| JP2016513467A5 (fr) | ||
| WO2022089353A1 (fr) | Anticorps à domaine unique ciblant bcma et son utilisation | |
| KR20160044063A (ko) | 항-pd1 항체 및 이의 치료 및 진단 용도 | |
| JP2014532074A5 (fr) | ||
| US20240101668A1 (en) | Polypeptides and their use in treatment of disease | |
| JPWO2021186056A5 (fr) | ||
| WO2024017362A1 (fr) | Récepteur antigénique chimérique ciblant gprc5d et/ou bcma, et son utilisation | |
| CN116789820A (zh) | 一种新型免疫调节剂的开发和应用 | |
| EP4247940A1 (fr) | Déplétion d'anticorps monoclonaux contre des cellules tueuses naturelles | |
| JPWO2021163389A5 (fr) | ||
| WO2019072274A1 (fr) | Anticorps monoclonal agoniste 4-1bb | |
| JPWO2020006568A5 (fr) |